08:00 , Dec 12, 2011 |  BioCentury  |  Emerging Company Profile

Sera Prognostics: Predicting preemies

Sera Prognostics Inc. is developing a molecular test that it thinks will accurately predict more than 90% of women at risk for preterm birth, allowing earlier monitoring and preventive treatment. The company raised $19.3 million...
07:00 , Apr 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Bipolar disorder Inter-alpha trypsin inhibitor heavy chain 1 (ITIH1); Inter-alpha trypsin inhibitor heavy chain 3 (ITIH3); guanine nucleotide binding protein-like-3 (GNL3);...